Javier Botín’s purchase of half of Sesderma values the dermocosmetics group at €200 million and places JB Capital in control amid a debt‑restructuring that makes Kartesia the main creditor
Executive summary: Javier Botín via JB Capital acquired a 50 % stake in Sesderma, valuing the group at €200 million, alongside a capital increase and debt restructuring that makes Kartesia the main creditor. The transaction shifts control of a leading Spanish dermocosmetics firm to JB Capital, introduces a major private‑debt investor into Sesderma’s capital structure, and signals Botín’s continued consolidation of mid‑size Spanish enterprises.
Who is involved: Javier Botín, JB Capital (investment arm), Sesderma’s shareholders and management, and the private‑debt firm Kartesia.
Likely next: Completion of the capital increase, formal transfer of control to JB Capital, and implementation of the debt‑restructuring plan under Kartesia’s oversight.
On July 23 2026, Javier Botín’s investment vehicle JB Capital agreed to acquire a 50 % stake in Spanish dermocosmetics company Sesderma, valuing the enterprise at approximately €200 million. The transaction includes a capital increase and a debt restructuring under which the private‑debt firm Kartesia becomes the company’s principal creditor. JB Capital will assume operational control of Sesderma, which reported roughly €140 million of revenue and €25 million of EBITDA. The deal reflects Botín’s continued focus on expanding his portfolio through majority‑holdings in mid‑size Spanish businesses.
Timeline
- — Javier Botín compra el 50% de Sesderma y valora el grupo dermocosmético en 200 millones (Expansión)
Analysis — what this means
Sectors affected
- Dermocosmetics
- Private equity
- Specialty lending
Historical parallels
- Javier Botín’s July 3 2026 acquisition of a stake in Palacios via Ñaming (Expansión, 2026‑07‑03)
Key entities
Sources
Open the full interactive case file on Beyond →
INTELLIGENCE
Social Pulse
AI estimate · not scraped